Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
Scientific presentation

Utilizing Single-Cell Multi-Omics to Uncover its Evolution and Resistance Mechanisms of AML


Cathy Smith, MD, UCSF
Description

Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy characterized by the overproduction of abnormal myeloblasts. Gene mutation-targeted therapies are a treatment option for patients with relapsed/refractory AML. For patients with FLT3 mutated AML, the FLT3 inhibitors (FLT3i), gilteritinib and quizartinib, can improve patient outcomes.

However, the development of secondary resistance to these drugs remains a major challenge. The acquisition of new mutations and the emergence of new subclones during the course of therapy can drive relapse. Although conventional bulk DNA sequencing can be used to identify the mutations in an entire sample, it cannot identify the mutations present in individual clones. Rather, deciphering the mechanisms of resistance to these drugs requires the dissection of AML at a single-cell level.

In this webinar, Dr. Catherine Smith, MD from the University of California, San Francisco discusses two studies that uncover mechanisms of resistance to gilteritinib and quizartinib. In both studies, Dr. Smith’s lab used serial single-cell DNA sequencing (using Mission Bio’s Tapestri Platform) to assess the clonal architecture of AML through treatment. She also discusses a third study using DNA antibody sequencing (DAb-seq) on the Tapestri Platform to demonstrate immunophenotypic and genotypic evolution on AML treatment.



VIEW


Scientific presentation
AMP 2021 Corporate Workshop: Single-cell DNA and multi-omics strategies for untangling therapy-resistant mechanisms in oncology
John Lee, M.D., Ph.D., Fred Hutchinson Cancer Research Center & Julia Gouffon, Ph.D., Mission Bio
Association for Molecular Pathology 2021 Digital Experience (2021)
Scientific presentation
Do More Single Cell with Less – Tapestri Platform Expansion for Hematologic Malignancy Research
Koichi Takahashi, MD, PhD, MD Anderson Cancer Center & Jim Flynn, PhD, Mission Bio
(2021)
Scientific presentation
Women in Single Cell: Elucidating Clonal Evolution and Clonotype-Immunophenotype Relationships in Myeloid Malignancies with Single-Cell Analysis
Linde Miles, PhD, Memorial Sloan Kettering Cancer Center
(2021)
Scientific presentation
Meet the Authors: Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies
Ross Levine, MD, Memorial Sloan Kettering Cancer Center
(2021)
REQUEST QUOTE